SCHEMBL847497

SCHEMBL847497

CC(=O)c1ccc(C)nc1NC1CCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 13/20 0.45
JAK2 O60674 1/20 0.42
JAK3 P52333 1/20 0.42
NR2F2 P24468 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
S1PR2 O95136 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
XBP1 P17861 1/20 0.40
RAB9A P51151 1/20 0.40
PPP1CA P62136 1/20 0.40
KMT2A Q03164 1/20 0.40
ADORA2A P29274 1/20 0.39
CHRM3 P20309 2/20 0.39
PDE4A P27815 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL848652 0.97 KDM4E (0.43) SYKJAK2JAK3NR2F2NPSR1
SCHEMBL847840 0.94 SYK (0.41) SYKJAK2JAK3NR2F2NPSR1
SCHEMBL849073 0.89 MAPK8 (0.49) SYKJAK2JAK3
SCHEMBL847489 0.87 OPRK1 (0.45) SYKMAPK1PDE4BOPRK1
SCHEMBL6644500 0.84 CHRM3 (0.44) SYKNR2F2NPSR1KDM4EMAPT
SCHEMBL847586 0.83 MAPK8 (0.45) SYKJAK3CHRM3PDE4APDE4B
SCHEMBL2100940 0.83 MAPK8 (0.45) SYKJAK3CHRM3PDE4APDE4B
SCHEMBL848330 0.83 MAPK8 (0.45) SYKJAK3CHRM3PDE4APDE4B
SCHEMBL846834 0.83 MAPK8 (0.41) SYKJAK2
SCHEMBL847031 0.80 BTK (0.39) SYKJAK2JAK3CHRM3PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163906-B2 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO, LLC (US) 2012-04-24 US disclosed
EP-2148862-B1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK HOFFMANN LA ROCHE (CH) 2012-03-28 EP disclosed
EP-2148862-A1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. Hoffmann-Roche AG (CH) 2010-02-03 EP disclosed
WO-2009015917-A2 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 WO disclosed
WO-2008138920-A1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2008-11-20 WO disclosed
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO LLC 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK MAPK9, MAPK10, MAPK1 SYK 598/4885JAK2 187/4885JAK3 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.